The clinical development of EGFR-TKIs offered a more efficacious and tolerable alternative to standard cytotoxic chemotherapy for patients with EGFR-mutated lung cancer, and this has profoundly altered the NSCLC treatment landscape in the past decade. This evidence concerns the gene EGFR and lung carcinoma.